Cargando…

A literature-based approach for curating gene signatures in multifaceted diseases

BACKGROUND AND AIMS: The task of identifying a representative and yet manageable target gene list for assessing the pathogenesis of complicated and multifaceted diseases is challenging. Using Inflammatory Bowel Disease (IBD) as an example, we conceived a bioinformatic approach to identify novel gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Garand, Mathieu, Kumar, Manoj, Huang, Susie Shih Yin, Al Khodor, Souhaila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350750/
https://www.ncbi.nlm.nih.gov/pubmed/32650786
http://dx.doi.org/10.1186/s12967-020-02408-7
Descripción
Sumario:BACKGROUND AND AIMS: The task of identifying a representative and yet manageable target gene list for assessing the pathogenesis of complicated and multifaceted diseases is challenging. Using Inflammatory Bowel Disease (IBD) as an example, we conceived a bioinformatic approach to identify novel genes associated with the various disease subtypes, in combination with known clinical control genes. METHODS: From the available literature, we used Acumenta Literature Lab(TM) (LitLab), network analyses, and LitLab Gene Retriever to assemble a gene pool that has a high likelihood of representing immunity-related subtype-specific signatures of IBD. RESULTS: We generated six relevant gene lists and 21 intersections that contain genes with unique literature associations to Crohn’s Disease (n = 60), Ulcerative Colitis (n = 17), and unclassified (n = 45) subtypes of IBD. From this gene pool, we then filtered and constructed, using network analysis, a final list of 142 genes that are the most representative of the disease and its subtypes. CONCLUSIONS: In this paper, we present the bioinformatic construction of a gene panel that putatively contains subtype signatures of IBD, a multifactorial disease. These gene signatures will be tested as biomarkers to classify patients with IBD, which has been a clinically challenging task. Such approach to diagnose and monitor complicated disease pathogenesis is a stepping-stone towards personalized care.